Immunonutrition-based solutions for diverse health applications

Publication ID: 24-11857525_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Immunonutrition-based solutions for diverse health applications,” Published Technical Disclosure No. 24-11857525_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857525_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,525.

Summary of the Inventive Concept

The inventive concept leverages the core technology of the original patent to develop novel applications and use cases in athletic performance, cognitive function, skin conditions, arthritis, and wound healing, demonstrating the versatility and broad potential of immunonutrition-based interventions.

Background and Problem Solved

The original patent addressed surgery-induced cachexia and expression of myeloid-derived suppressor cells and pro-inflammatory cytokines. However, the underlying technology has broader implications for human health. This inventive concept seeks to expand the application scope of immunonutrition supplements to tackle diverse health challenges, capitalizing on the benefits of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides.

Detailed Description of the Inventive Concept

The new claims encompass a range of innovative applications, including athletic performance optimization, cognitive function enhancement in individuals with attention deficit hyperactivity disorder, treatment of skin conditions, reduction of inflammation in arthritis, and improved wound healing. Each application leverages the immunonutrition supplement's ability to modulate the immune response, with tailored dosages and formulations to address specific health needs. The athletic performance system, for instance, provides between 5 g and 30 g of L-arginine per day, while the cognitive function method delivers 1.0 g to 5.0 g of eicosapentaenoic acid and docosahexaenoic acid in total per day.

Novelty and Inventive Step

The new claims introduce novel and non-obvious applications of the original patent's technology, demonstrating a significant expansion of its utility and scope. The inventive step lies in recognizing the potential of immunonutrition supplements to address diverse health challenges, and developing targeted formulations and dosages to achieve specific health benefits.

Alternative Embodiments and Variations

Alternative embodiments may include varying the ratio of L-arginine to omega-3 fatty acids, or incorporating additional nutrients to enhance the immunonutrition supplement's efficacy. Variations could also involve adapting the supplement for different delivery forms, such as injectables or oral capsules, to accommodate diverse patient needs and preferences.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential across various industries, including sports nutrition, cognitive health, dermatology, and wound care. The target market encompasses a broad range of consumers, from professional athletes to individuals seeking to improve their overall health and wellbeing.

Field of Art

Nutritional supplementation and immunonutrition, specifically focused on medical interventions involving specialized nutrient compositions for modulating physiological responses

Person of Ordinary Skill (PHOSITA) Profile

A nutritional scientist or medical researcher with expertise in immunonutrition, understanding of nutrient interactions, and knowledge of supplement formulation techniques across various health conditions

Obviousness Rationale

A PHOSITA would recognize the fundamental immunomodulatory principles of the source patent's nutrient combination and understand its potential applicability across multiple physiological contexts. The core composition of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides represents a versatile intervention strategy with broad potential for addressing inflammatory and metabolic processes. Given the established mechanism of action demonstrated in the original patent, extending these principles to additional health domains would be a predictable and logical progression for a skilled practitioner.

Obvious Combinations & Variations

Source Patent Element
Specialized immunonutrition supplement for treating surgery-induced cachexia
PTD Variation
Athletic performance optimization using identical nutrient composition
Obviousness Reasoning
Known technique of applying immunonutritional interventions to performance enhancement, with predictable physiological modulation mechanisms
Source Patent Element
Daily dosage ranges for L-arginine and omega-3 fatty acids
PTD Variation
Cognitive function enhancement for ADHD patients using similar dosage parameters
Obviousness Reasoning
Finite set of known effective nutrient ranges, with established neurological inflammatory modulation potential
Source Patent Element
Nutrient combination targeting inflammatory responses
PTD Variation
Topical application for skin conditions and wound healing
Obviousness Reasoning
Predictable extension of anti-inflammatory mechanism to dermatological interventions, representing a design choice within known therapeutic approaches
Source Patent Element
Immunonutrition supplement targeting cellular metabolic processes
PTD Variation
Arthritis inflammation reduction using vitamin A dosage
Obviousness Reasoning
Recognized inflammatory modulation potential of nutrients, representing a straightforward adaptation of known therapeutic principles
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in this publication would have been obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable extensions of the foundational immunonutritional principles established in US Patent 11857525, demonstrating no inventive step beyond the ordinary capabilities of a skilled practitioner in nutritional intervention strategies.

Original Patent Information

Patent NumberUS 11,857,525
TitleTreatment or prevention of surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines
Assignee(s)SOCIÉTÉ DES PRODUITS NESTLÉ S.A.